NextFerm Technologies : Capital Market Presentation

NEXTFERM

TECHNOLOGIES

Leading The Alternative

Protein Revolution

April-2024

DISCLAIMER

2

This presentation is intended for the provision of non-comprehensive information for the sake of convenience solely. You are hereby referred to the full prospectus and immediate and periodic reports filed by the company with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. for information regarding the Company's activities and the risks entailed thereby, including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, that is included therein. In case of any discrepancy between the information contained herein and the information contained in the official reports of the Company to the Israeli Securities Authority and the Tel Aviv Stock Exchange, the information recorded in such reports shall prevail.

This presentation may include forward-looking statements and forward- looking information, including, but not limited to developments, outlooks, projected economy measures, etc.. Such forward-looking statements and information are based on the current assumptions, intentions and plans of the Company. The forward-looking information in the presentation is subject to risks and uncertainties and may not materialize, in whole or in part, or may materialize significantly differently than as predicted, or may be affected by various factors, including factors that are not under the Company's control or such that cannot be estimated in advance. The Company makes no representation or warranty of any kind with respect to such information.

For the avoidance of doubt, it is clarified that the Company does not undertake to update and/or modify the information included in this presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation.

This presentation does not constitute an offer, invitation or recommendation to purchase, sell, subscribe for or do any transactions in the securities of the Company, in any jurisdiction, and the information provided in this presentation is not a basis for the making of any investment decision, nor a recommendation or opinion, nor a substitute for the discretion and independent analysis of any potential investor.

This presentation includes information from public sources, which was not independently examined by the Company and the Company is not liable as to its accuracy.

ABOUT NEXTFERM

LEADING THE ALTERNATIVE PROTEIN REVOLUTION

Experienced team in the world of Nutrition and food-tech

ProteVin™ - The only vegan protein with animal like nutritional value and neutral taste Innovative technology based

Demands for ProteVin™ from the growing alternative protein market

Production has started following scale up and launch - based on a profitable process

3

NEXTFERM

The team

Experienced Team in the Food and Food-tech Industries

Company management is comprised of former Senior Management of Enzymotec, which developed innovative ingredients within the world of nutrition.

Enzymotec reached revenues of over $80M and went public (NASDAQ) during 2013,

with a market cap of $300M

4

4

ProteVin was tested and approved as appropriate for wide variety of food and dietary supplement products

5

"Every Tenth Portion of Meat, Eggs, Dairy, and Seafood Eaten Around the

Globe Will Be Made from Alternative Proteins by 2035, "

BY 2035, THE ALTERNATIVE PROTEIN MARKET (B2C)

IS EXPECTED TO REACH AT LEAST

$290B(*)

(*)https://www.bcg.com/press/23march2021-alternative-protein-market-reach-290-billion-by-2035

6

OVER $300M(*)

YEARLY GROWTH IN DEMAND FOR VEGAN PROTEIN POWDER

1. https://www.gminsights.com/industry-analysis/vegan-protein-powder-marketGrowth for 2022 and forecast for 2032

7

- COMMERCIAL STATUS

Above 100 food and	• 5 launches	Above $3M
dietary supplement	• Many Customers
in PO's & Supply
companies are evaluating	are waiting for ProteVIn™.
Agreement
ProteVin™

8

5 LAUNCHES

9

10